Stock Track | Cellebrite Stock Plummets 10.87% Despite Strong Q4 Results and Upbeat Outlook

Stock Track
02-13

Cellebrite DI Ltd (NASDAQ: CLBT), a leading provider of digital intelligence solutions, saw its stock price plummet by 10.87% in pre-market trading on Thursday, February 13, 2025, despite reporting solid fourth-quarter and full-year 2024 financial results.

For the fourth quarter of 2024, Cellebrite reported adjusted earnings of $0.10 per share, meeting analyst expectations. The company's revenue rose 17.2% year-over-year to $109 million, surpassing analyst estimates of $107.18 million. This strong performance was driven by a 21% increase in subscription revenue.

For the full year 2024, Cellebrite's revenue reached $401.2 million, up 23% from the previous year. The company achieved an adjusted EBITDA margin of 24.8%, showcasing its ability to generate robust profitability and cash flow.

Looking ahead, Cellebrite provided an optimistic outlook for the first quarter of 2025 and the full year. The company expects revenue in the range of $480 million to $490 million for 2025, representing a growth of 20% to 22% compared to 2024. Additionally, Cellebrite forecasts an adjusted EBITDA margin of 24% to 25% for the full year.

Despite the strong financial performance and positive guidance, Cellebrite's stock price experienced a significant decline, suggesting a potential overreaction from the market. Analysts and industry experts have praised the company's execution and its ability to capitalize on the growing demand for digital intelligence solutions.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10